The Risk of Ischemic Cardio- and Cerebrovascular Events Associated with Oxycodone–Naloxone and Other Extended-Release High-Potency Opioids: A Nested Case–Control Study
In Germany, an extended-release (ER) combination of the high-potency opioid (HPO) oxycodone and the antagonist naloxone was approved in 2006. In recent years, the cardio- and cerebrovascular safety of opioid antagonists and of opioids themselves has been discussed.
The objective of this study was to estimate the risk of major ischemic cardio- and cerebrovascular events in patients receiving ER oxycodone–naloxone compared with those receiving other ER HPOs.
We used the German Pharmacoepidemiological Research Database (GePaRD) to conduct a nested case–control study (2006–2011) within a cohort of ER HPO users. Cases were defined as patients hospitalized for acute myocardial infarction (MI) or ischemic stroke (IS). For each case, up to ten controls were selected by risk-set sampling. Using conditional logistic regression, confounder-adjusted odds ratios (aORs) and 95% confidence intervals (CIs) were obtained for the risk of MI/IS associated with (1) current HPO treatment, (2) recent discontinuation, or (3) recent switch of HPO therapy compared with past treatment.
In 309,936 ER HPO users, 12,384 MI/IS events were detected, resulting in a crude incidence rate of 19.48 (95% CI 19.14–19.82) per 1000 person years. A small but significantly elevated aOR was found for morphine (1.12; 95% CI 1.04–1.22) but not for oxycodone–naloxone. Recent discontinuation and recent switch of any ER HPO also had a significant impact on the outcome (aOR 1.12; 95% CI 1.04–1.21 and 1.25; 95% CI 1.03–1.52, respectively).
Our study does not indicate an association between oxycodone–naloxone and ischemic cardio- or cerebrovascular events. However, our findings do suggest that every change in ER HPO therapy should be conducted with caution.
- 2.Frenk SM, Porter KS, Paulozzi LJ. Prescription opioid analgesic use among adults: United States, 1999–2012. NCHS Data Brief no. 189. Hyattsville, MD: National Center for Health Statistics. 2015; 1–8. https://www.cdc.gov/nchs/data/databriefs/db189.pdf.
- 7.Mundipharma. Summary of Products Characteristics Targin. 2016. http://www.mundipharma.de/downloadFile/fi-targinpdf-00000522.html?tx_extbasefal_pi1[action]=showDownloadInfo&cHash=c71d2ad24d70fc022c45a65938caaa72. Accessed 5 Feb 2017.
- 9.US Food and Drug Administration. FDA approves new extended-release oxycodone with abuse-deterrent properties. 2014. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm406407.htm. Accessed 11 Jan 2016.
- 10.Purdue Pharma. TARGINIQ ER Prescribing Information. Stamford, CT: Purdue Pharma L.P.; 2014. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/205777lbl.pdf. Accessed 1 April 2016.
- 11.US Food and Drug Administration; Center for Drug Evaluation and Research. Briefing document. Anesthetic and Analgesic Drug Products Advisory Committee Meeting. June 11-12, 2014. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AnestheticAndAnalgesicDrugProductsAdvisoryCommittee/UCM400205.pdf. Accessed 4 Nov 2015.
- 12.US Food and Drug Administration (FDA). Entereg (alvimopan) capsules. Silver Spring, MD: US DFA; 2013. http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm194328.htm. Accessed 31 Jan 2016.
- 14.AstraZeneca AB. Summary of Product Characteristics Moventig. Södertälje: AstraZeneca AB; 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002810/WC500179075.pdf. Accessed 18 May 2016.
- 15.Wyeth Lederle. Summary of Product Characteristics Relistor. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000870/WC500050562.pdf. Accessed 18 May 2016.
- 26.Hoffmann F. Stark wirkende Opioide. In: Glaeske G, Schicktanz C, editors. BARMER GEK Arzneimittelreport 2012. 14th ed. Siegburg: Asgard Verlagsservice GmbH; 2012. p. 113–30.Google Scholar
- 27.Arzneitelegramm. Oxycodon plus Naloxon (Targin): Was gibt es neues? 2010. http://www.arznei-telegramm.de/html/2010_05/1005051_01.html. Accessed 13 Nov 2015.
- 33.Fassmer A, Schink T. Representativity of outpatient drug prescriptions in the German Pharmacoepidemiological Research Database (GePaRD) In: Annual Conference of the German Society for Epidemiology (DGEpi); 17–20 Sept 2014; Ulm, p. 208. http://dgepi.de/fileadmin/pdf/tagungen_workshops/Programmheft_DGEpi_2014.pdf.
- 34.Tumorschmerzen [Empfehlungen zur Therapie von Tumorschmerzen]. 3rd ed. Köln: Drug Commission of the German Medical Association; 2007.Google Scholar
- 35.The Association of the Scientific Medical Societies in Germany (AWMF). S3 guideline LONTS. Long-term administration of opioids for non-tumor pain (Update 01/2015). http://www.awmf.org/uploads/tx_szleitlinien/145-003l_S3_LONTS_2015-01.pdf. Accessed 15 Oct 2015.
- 38.Masclee G, Sturkenboom M, Leal I, De Berardis G, Bezemer I, Gil M, et al. Harmonization of Acute Myocardial Infarction Identification from Different Databases in the SAFEGUARD Project. Abstracts of the 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 25–28 Aug 2013, Montréal, Canada. Pharmacoepidemiol Drug Saf. 2013;22, p. s1:276.Google Scholar
- 39.Schmedt N, Gil M, Martin E, Requena G, Bezemer I, De Berardis G, et al. Harmonization of Outcome Extraction for Ischemic and Hemorrhagic Stroke Across Data Sources in the SAFEGUARD Project. Abstracts of the 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, 25–28 Aug 2013, Montréal, Canada. Pharmacoepidemiol Drug Saf. 2013;22, p. s1:307.Google Scholar